Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

DBVT vs PRGO vs HLN vs ALKS vs JNJ

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-21.6%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-72.0%
HLN
Haleon plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • GB
Market Cap$41.45B
5Y Perf.+32.4%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+38.3%
JNJ
Johnson & Johnson

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$536.23B
5Y Perf.+27.5%

DBVT vs PRGO vs HLN vs ALKS vs JNJ — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DBVT logoDBVT
PRGO logoPRGO
HLN logoHLN
ALKS logoALKS
JNJ logoJNJ
IndustryBiotechnologyDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericBiotechnologyDrug Manufacturers - General
Market Cap$1712.35T$1.61B$41.45B$5.90B$536.23B
Revenue (TTM)$0.00$4.18B$22.01B$1.56B$92.15B
Net Income (TTM)$-168M$-1.82B$3.18B$153M$25.12B
Gross Margin34.2%63.9%65.4%68.1%
Operating Margin-4.1%21.4%12.3%26.1%
Forward P/E5.6x22.2x24.8x19.2x
Total Debt$22M$3.97B$8.59B$70M$36.63B
Cash & Equiv.$194M$532M$1.32B$1.12B$24.11B

DBVT vs PRGO vs HLN vs ALKS vs JNJLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DBVT
PRGO
HLN
ALKS
JNJ
StockJul 22May 26Return
DBV Technologies S.… (DBVT)10078.4-21.6%
Perrigo Company plc (PRGO)10028.0-72.0%
Haleon plc (HLN)100132.4+32.4%
Alkermes plc (ALKS)100138.3+38.3%
Johnson & Johnson (JNJ)100127.5+27.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: DBVT vs PRGO vs HLN vs ALKS vs JNJ

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: JNJ leads in 4 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and profitability and margin quality. Perrigo Company plc is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. DBVT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT ranks third and is worth considering specifically for momentum.

  • +110.4% vs PRGO's -51.2%
Best for: momentum
PRGO
Perrigo Company plc
The Value Play

PRGO is the #2 pick in this set and the best alternative if value and dividends is your priority.

  • Lower P/E (5.6x vs 19.2x)
  • 9.8% yield, 10-year raise streak, vs JNJ's 2.2%, (2 stocks pay no dividend)
Best for: value and dividends
HLN
Haleon plc
The Value Pick

HLN is the clearest fit if your priority is valuation efficiency.

  • PEG 2.63 vs JNJ's 34.17
Best for: valuation efficiency
ALKS
Alkermes plc
The Defensive Pick

ALKS is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
Best for: sleep-well-at-night
JNJ
Johnson & Johnson
The Income Pick

JNJ carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 36 yrs, beta 0.06, yield 2.2%
  • Rev growth 4.3%, EPS growth -57.8%, 3Y rev CAGR 4.1%
  • 132.3% 10Y total return vs ALKS's -11.0%
  • Beta 0.06, yield 2.2%, current ratio 1.11x
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthJNJ logoJNJ4.3% revenue growth vs DBVT's -100.0%
ValuePRGO logoPRGOLower P/E (5.6x vs 19.2x)
Quality / MarginsJNJ logoJNJ27.3% margin vs PRGO's -43.5%
Stability / SafetyJNJ logoJNJBeta 0.06 vs DBVT's 1.26
DividendsPRGO logoPRGO9.8% yield, 10-year raise streak, vs JNJ's 2.2%, (2 stocks pay no dividend)
Momentum (1Y)DBVT logoDBVT+110.4% vs PRGO's -51.2%
Efficiency (ROA)JNJ logoJNJ13.0% ROA vs DBVT's -89.0%

DBVT vs PRGO vs HLN vs ALKS vs JNJ — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

DBVTDBV Technologies S.A.

Segment breakdown not available.

PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
HLNHaleon plc
FY 2022
Respiratory Health
100.0%$1.6B
ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
JNJJohnson & Johnson
FY 2024
Innovative Medicine
64.1%$57.0B
MedTech
35.9%$31.9B

DBVT vs PRGO vs HLN vs ALKS vs JNJ — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJNJLAGGINGALKS

Income & Cash Flow (Last 12 Months)

JNJ leads this category, winning 3 of 6 comparable metrics.

JNJ and DBVT operate at a comparable scale, with $92.1B and $0 in trailing revenue. JNJ is the more profitable business, keeping 27.3% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricDBVT logoDBVTDBV Technologies …PRGO logoPRGOPerrigo Company p…HLN logoHLNHaleon plcALKS logoALKSAlkermes plcJNJ logoJNJJohnson & Johnson
RevenueTrailing 12 months$0$4.2B$22.0B$1.6B$92.1B
EBITDAEarnings before interest/tax-$112M$58M$5.3B$212M$31.4B
Net IncomeAfter-tax profit-$168M-$1.8B$3.2B$153M$25.1B
Free Cash FlowCash after capex-$151M$108M$3.1B$392M$19.1B
Gross MarginGross profit ÷ Revenue+34.2%+63.9%+65.4%+68.1%
Operating MarginEBIT ÷ Revenue-4.1%+21.4%+12.3%+26.1%
Net MarginNet income ÷ Revenue-43.5%+14.5%+9.8%+27.3%
FCF MarginFCF ÷ Revenue+2.6%+14.2%+25.1%+20.7%
Rev. Growth (YoY)Latest quarter vs prior year-7.2%-0.4%+28.2%+6.8%
EPS Growth (YoY)Latest quarter vs prior year+91.5%-56.4%+18.8%-4.1%+91.0%
JNJ leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 6 of 7 comparable metrics.

At 19.0x trailing earnings, HLN trades at a 51% valuation discount to JNJ's 38.4x P/E. Adjusting for growth (PEG ratio), HLN offers better value at 2.25x vs JNJ's 34.17x — a lower PEG means you pay less per unit of expected earnings growth.

MetricDBVT logoDBVTDBV Technologies …PRGO logoPRGOPerrigo Company p…HLN logoHLNHaleon plcALKS logoALKSAlkermes plcJNJ logoJNJJohnson & Johnson
Market CapShares × price$1712.35T$1.6B$41.4B$5.9B$536.2B
Enterprise ValueMkt cap + debt − cash$1712.35T$5.1B$51.3B$4.9B$548.8B
Trailing P/EPrice ÷ TTM EPS-0.76x-1.14x19.01x24.76x38.43x
Forward P/EPrice ÷ next-FY EPS est.5.56x22.22x19.20x
PEG RatioP/E ÷ EPS growth rate2.25x34.17x
EV / EBITDAEnterprise value multiple7.42x13.62x17.25x18.61x
Price / SalesMarket cap ÷ Revenue0.38x2.83x4.00x6.04x
Price / BookPrice ÷ Book value/share0.66x0.55x1.87x3.28x7.56x
Price / FCFMarket cap ÷ FCF11.12x15.47x12.28x27.02x
PRGO leads this category, winning 6 of 7 comparable metrics.

Profitability & Efficiency

JNJ leads this category, winning 5 of 9 comparable metrics.

JNJ delivers a 31.7% return on equity — every $100 of shareholder capital generates $32 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), HLN scores 8/9 vs PRGO's 4/9, reflecting strong financial health.

MetricDBVT logoDBVTDBV Technologies …PRGO logoPRGOPerrigo Company p…HLN logoHLNHaleon plcALKS logoALKSAlkermes plcJNJ logoJNJJohnson & Johnson
ROE (TTM)Return on equity-130.2%-50.7%+19.9%+8.8%+31.7%
ROA (TTM)Return on assets-89.0%-19.8%+10.0%+5.4%+13.0%
ROICReturn on invested capital+3.7%+7.6%+18.9%+20.7%
ROCEReturn on capital employed-145.7%+4.3%+8.6%+14.2%+17.6%
Piotroski ScoreFundamental quality 0–944875
Debt / EquityFinancial leverage0.13x1.35x0.52x0.04x0.51x
Net DebtTotal debt minus cash-$172M$3.4B$7.3B-$1.0B$12.5B
Cash & Equiv.Liquid assets$194M$532M$1.3B$1.1B$24.1B
Total DebtShort + long-term debt$22M$4.0B$8.6B$70M$36.6B
Interest CoverageEBIT ÷ Interest expense-189.82x-7.20x7.80x32.30x48.23x
JNJ leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

JNJ leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors JNJ at 13.5% vs PRGO's -25.2% — a key indicator of consistent wealth creation.

MetricDBVT logoDBVTDBV Technologies …PRGO logoPRGOPerrigo Company p…HLN logoHLNHaleon plcALKS logoALKSAlkermes plcJNJ logoJNJJohnson & Johnson
YTD ReturnYear-to-date+4.9%-13.5%-5.6%+25.3%+7.9%
1-Year ReturnPast 12 months+110.4%-51.2%-11.7%+16.5%+44.8%
3-Year ReturnCumulative with dividends+19.7%-58.1%+10.4%+14.5%+46.3%
5-Year ReturnCumulative with dividends-69.1%-60.1%+31.7%+60.9%+46.1%
10-Year ReturnCumulative with dividends-87.0%-77.7%+31.7%-11.0%+132.3%
CAGR (3Y)Annualised 3-year return+6.2%-25.2%+3.4%+4.6%+13.5%
JNJ leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ALKS and JNJ each lead in 1 of 2 comparable metrics.

JNJ is the less volatile stock with a 0.06 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricDBVT logoDBVTDBV Technologies …PRGO logoPRGOPerrigo Company p…HLN logoHLNHaleon plcALKS logoALKSAlkermes plcJNJ logoJNJJohnson & Johnson
Beta (5Y)Sensitivity to S&P 5001.26x1.18x0.06x1.06x0.06x
52-Week HighHighest price in past year$26.18$28.44$11.42$36.60$251.71
52-Week LowLowest price in past year$7.53$9.23$8.71$25.17$146.12
% of 52W HighCurrent price vs 52-week peak+76.3%+41.2%+81.5%+96.7%+88.4%
RSI (14)Momentum oscillator 0–10048.160.936.060.237.1
Avg Volume (50D)Average daily shares traded252K3.4M8.0M2.3M7.0M
Evenly matched — ALKS and JNJ each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — PRGO and JNJ each lead in 1 of 2 comparable metrics.

Analyst consensus: DBVT as "Buy", PRGO as "Hold", HLN as "Buy", ALKS as "Buy", JNJ as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 9.6% for HLN (target: $10). For income investors, PRGO offers the higher dividend yield at 9.81% vs HLN's 1.94%.

MetricDBVT logoDBVTDBV Technologies …PRGO logoPRGOPerrigo Company p…HLN logoHLNHaleon plcALKS logoALKSAlkermes plcJNJ logoJNJJohnson & Johnson
Analyst RatingConsensus buy/hold/sellBuyHoldBuyBuyBuy
Price TargetConsensus 12-month target$46.33$20.00$10.20$44.00$249.27
# AnalystsCovering analysts153642840
Dividend YieldAnnual dividend ÷ price+9.8%+1.9%+2.2%
Dividend StreakConsecutive years of raises0102036
Dividend / ShareAnnual DPS$1.15$0.13$4.87
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+2.1%+0.5%+0.5%
Evenly matched — PRGO and JNJ each lead in 1 of 2 comparable metrics.
Key Takeaway

JNJ leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 1 (Valuation Metrics). 2 tied.

Best OverallJohnson & Johnson (JNJ)Leads 3 of 6 categories
Loading custom metrics...

DBVT vs PRGO vs HLN vs ALKS vs JNJ: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is DBVT or PRGO or HLN or ALKS or JNJ a better buy right now?

For growth investors, Johnson & Johnson (JNJ) is the stronger pick with 4.

3% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Haleon plc (HLN) offers the better valuation at 19. 0x trailing P/E (22. 2x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — DBVT or PRGO or HLN or ALKS or JNJ?

On trailing P/E, Haleon plc (HLN) is the cheapest at 19.

0x versus Johnson & Johnson at 38. 4x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Haleon plc wins at 2. 63x versus Johnson & Johnson's 34. 17x.

03

Which is the better long-term investment — DBVT or PRGO or HLN or ALKS or JNJ?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: JNJ returned +132. 3% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — DBVT or PRGO or HLN or ALKS or JNJ?

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 2106% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — DBVT or PRGO or HLN or ALKS or JNJ?

By revenue growth (latest reported year), Johnson & Johnson (JNJ) is pulling ahead at 4.

3% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Haleon plc grew EPS 12. 5% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — DBVT or PRGO or HLN or ALKS or JNJ?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is DBVT or PRGO or HLN or ALKS or JNJ more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Haleon plc (HLN) is the more undervalued stock at a PEG of 2. 63x versus Johnson & Johnson's 34. 17x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Perrigo Company plc (PRGO) trades at 5. 6x forward P/E versus 22. 2x for Haleon plc — 16. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — DBVT or PRGO or HLN or ALKS or JNJ?

In this comparison, PRGO (9.

8% yield), JNJ (2. 2% yield), HLN (1. 9% yield) pay a dividend. DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.

09

Is DBVT or PRGO or HLN or ALKS or JNJ better for a retirement portfolio?

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +132. 3% 10Y return). Both have compounded well over 10 years (JNJ: +132. 3%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between DBVT and PRGO and HLN and ALKS and JNJ?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DBVT is a mega-cap quality compounder stock; PRGO is a small-cap income-oriented stock; HLN is a mid-cap quality compounder stock; ALKS is a small-cap quality compounder stock; JNJ is a large-cap quality compounder stock. PRGO, HLN, JNJ pay a dividend while DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Stocks Like

HLN

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 8%
  • Dividend Yield > 0.7%
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

JNJ

Dividend Mega-Cap Quality

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 16%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.